[Contribution to the knowledge of the biology of Moniliformis moniliformis Bremser, 1811 (Acanthocephala). Influence of host resistance of Rattus norvegicus Berkenhout, 1769, on the parasite (author's transl)]

Important note: Information in this article was accurate in 1982. The state of the art may have changed since the publication date.

Ann Parasitol Hum Comp. 1981;56(4):407-21. Unique Identifier : AIDSLINE MED/82111906
Miremad-Gassmann M

Abstract: Acquired resistance in rats (SIV 50) during infection with 30 Moniliformis moniliformis has an effect on survival, growth and behaviour of the parasite. We observe an expulsion of worms during infection, starting in the 4th week for female worms but usually after 8 weeks for the males. The density of parasites determines the beginning of the self-cure. Comparing our results with the works of Andreassen (1974a) and Burlingame et Chandler (1941), we observe that the self-cure occurs earlier with doses of 100 larvae than with 30 or 20. Rats with a primary infection show immunity against reinfection. Two weeks after reinfection we observe that only 26% of the parasites are fixed compared to 66% in primary infections. A major effect of immunity is retardation of worm growth. Parasites from reinfections are shorter than those of primary infections. During infection the worm migrate. After the first 3 weeks the male migrate posteriorly and female anteriorly and posteriorly. In reinfections parasites become localized after only 2 weeks. We hypothize that M. moniliformis migrates due to an immunological reaction and inflammatory response of the intestinal mucus but also as a part of its own normal development.

Keywords: Acanthocephala/*PHYSIOLOGY Animal English Abstract Female Helminthiasis/*IMMUNOLOGY/PARASITOLOGY Immunity, Active Intestines/PARASITOLOGY Male Moniliformis/*PHYSIOLOGY Movement Rats JOURNAL ARTICLE

820530
M8250009

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1982. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1982. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .